Edition 1, 2020
ACH2 Grant Awarded for the Validation of VL-Plasma® Device for use in HTLV Proviral Load and Antibody Testing
NRL Principal Scientist A/Prof Rosemary Ffrench and collaborators from the Burnet, Baker and Peter Doherty Institutes were successful in their application for an ACH2 grant for the: Validation of VL-Plasma® device for use in HTLV proviral load and antibody testing.
This study, which commenced in January 2020, will use the VL-Plasma device (pictured below) developed by A/Prof David Anderson and his team at the Global Health Diagnostic Development Laboratory at the Burnet Institute, to isolate plasma and cells from whole blood for testing using the NRL HTLV proviral load assay, developed by Dr Kim Wilson (NRL Senior Scientist – R&D). Plasma will be tested for HTLV antibodies using the DiaSorin Liaison HTLV I/II CLIA assay. If successful, this will lead to better access to HTLV testing for remote indigenous communities.